Dopamine transporter as target for drug development of cocaine dependence medications.
about
Further structure-activity relationship studies on 4-((((3S,6S)-6-benzhydryltetrahydro-2H-pyran-3-yl)amino)methyl)phenol: identification of compounds with triple uptake inhibitory activity as potential antidepressant agents.Dopamine transporter-related effects of modafinil in rhesus monkeys.Unfaithful neurotransmitter transporters: focus on serotonin uptake and implications for antidepressant efficacyRegulation of the Dopamine and Vesicular Monoamine Transporters: Pharmacological Targets and Implications for Disease.Interaction of cocaine-, benztropine-, and GBR12909-like compounds with wild-type and mutant human dopamine transporters: molecular features that differentially determine antagonist-binding properties.Interaction of tyrosine 151 in norepinephrine transporter with the 2β group of cocaine analog RTI-113.Antagonist-induced conformational changes in dopamine transporter extracellular loop two involve residues in a potential salt bridgeFurther structure-activity relationship studies on 8-substituted-3-[2-(diarylmethoxyethylidenyl)]-8-azabicyclo[3.2.1]octane derivatives at monoamine transporters.Synthesis and structure-activity relationship studies of 3-biaryl-8-oxabicyclo[3.2.1]octane-2-carboxylic acid methyl esters.Effects of buspirone on the immediate positive and delayed negative properties of intravenous cocaine as measured in the conditioned place preference testThe solute carrier 6 family of transportersSynthesis and biological characterization of (3R,4R)-4-(2-(benzhydryloxy)ethyl)-1-((R)-2-hydroxy-2-phenylethyl)-piperidin-3-ol and its stereoisomers for activity toward monoamine transporters.DAT/SERT selectivity of flexible GBR 12909 analogs modeled using 3D-QSAR methods.Further structural optimization of cis-(6-benzhydryl-piperidin-3-yl)-benzylamine and 1,4-diazabicyclo[3.3.1]nonane derivatives by introducing an exocyclic hydroxyl group: interaction with dopamine, serotonin, and norepinephrine transporters.Synthesis and receptor binding properties of 2beta-alkynyl and 2beta-(1,2,3-triazol)substituted 3beta-(substituted phenyl)tropane derivatives.The binding sites for benztropines and dopamine in the dopamine transporter overlap.Synthesis and monoamine transporter binding properties of 2beta-[3'-(substituted benzyl)isoxazol-5-yl]- and 2beta-[3'-methyl-4'-(substituted phenyl)isoxazol-5-yl]-3beta-(substituted phenyl)tropanes.Prediction of functional class of proteins and peptides irrespective of sequence homology by support vector machines.Comparative modeling of the human monoamine transporters: similarities in substrate binding.Establishment of cell-free electrophysiology for ion transporters: application for pharmacological profiling.The role of human dopamine transporter in NeuroAIDS.Singular value decomposition analysis of the torsional angles of dopamine reuptake inhibitor GBR 12909 analogs: effect of force field and charges.The dopamine uptake inhibitor 3 alpha-[bis(4'-fluorophenyl)metoxy]-tropane reduces cocaine-induced early-gene expression, locomotor activity, and conditioned reward.Structure-Activity Relationship Studies on a Series of 3α-[Bis(4-fluorophenyl)methoxy]tropanes and 3α-[Bis(4-fluorophenyl)methylamino]tropanes As Novel Atypical Dopamine Transporter (DAT) Inhibitors for the Treatment of Cocaine Use Disorders.Determination of the enantiomeric purity of the selective dopamine transporter inhibitor (+)-R,R-4-(2-benzhydryloxyethyl)-1-(4-fluorobenzyl)piperidin-3-ol.
P2860
Q24603864-0FC8BEFE-861E-4F0C-9C1A-D2454EFB52F2Q24608414-75495859-5EFD-4E45-9599-4F43D4D8E3D8Q24658095-82DEF15F-18B8-4BDC-97E0-CA62800B8743Q34673305-09A2A779-BD9A-4FEE-83FE-A8E4CF2CD681Q34825605-9C20F4D3-1887-4606-9466-313B8A989FE9Q35017258-985302B3-E15F-4689-8935-97FB564BEDFAQ35383366-2C51E121-5BD5-4C0A-BAAF-EC9CD9F80B12Q35590737-D71B28EC-1965-4FDB-BC4E-17ABCDB5A783Q35939405-B2674DCA-1817-4448-B916-7F9D733F902CQ35942229-E24C1734-234F-400E-AF5C-1FD30527704AQ36346899-B700E92D-9B71-46C6-BF2F-98D8272511A7Q36453107-AF51CAE6-D15D-4285-A28A-845E53FDE852Q36484691-6675DC1D-769C-4B51-932D-6BF6BD58A92AQ36596750-F33E560F-80EE-4074-8168-EEA0BC7DAB99Q36980311-91DF109B-3F9B-4A17-B750-DF8D10F1471FQ36990361-34D239FB-AAFF-4F92-B154-14FCD7466C6FQ37003610-4050E76B-DF0B-4FA0-880F-8AA6EB9C633EQ37462980-B984C409-9B9A-46D3-9251-90AB6420F4F5Q39192034-7AC09D25-3C0E-4747-B7DA-B2D6BC1754C1Q40313784-8C5FAFC0-A73F-40F7-B2A4-95643BB2F708Q41922188-9BFC5D6A-E726-4133-A4C4-1A65B8477817Q44638810-80DB13FB-9869-4672-A9EC-A140C46A49CDQ45928219-B5269A50-0EC5-4655-985C-D4DBF00EE251Q48141734-0FD82133-C0EA-4CFF-A752-33031A112816Q48239921-599EE30D-78D9-4338-B96D-5C193214E86B
P2860
Dopamine transporter as target for drug development of cocaine dependence medications.
description
2003 nî lūn-bûn
@nan
2003 թուականի Հոկտեմբերին հրատարակուած գիտական յօդուած
@hyw
2003 թվականի հոտեմբերին հրատարակված գիտական հոդված
@hy
2003年の論文
@ja
2003年論文
@yue
2003年論文
@zh-hant
2003年論文
@zh-hk
2003年論文
@zh-mo
2003年論文
@zh-tw
2003年论文
@wuu
name
Dopamine transporter as target for drug development of cocaine dependence medications.
@ast
Dopamine transporter as target for drug development of cocaine dependence medications.
@en
type
label
Dopamine transporter as target for drug development of cocaine dependence medications.
@ast
Dopamine transporter as target for drug development of cocaine dependence medications.
@en
prefLabel
Dopamine transporter as target for drug development of cocaine dependence medications.
@ast
Dopamine transporter as target for drug development of cocaine dependence medications.
@en
P2093
P1476
Dopamine transporter as target for drug development of cocaine dependence medications
@en
P2093
Maarten E A Reith
Rohit Kolhatkar
Shijun Zhang
P304
P356
10.1016/J.EJPHAR.2003.08.060
P407
P577
2003-10-01T00:00:00Z